0001209191-20-058828.txt : 20201117 0001209191-20-058828.hdr.sgml : 20201117 20201117173744 ACCESSION NUMBER: 0001209191-20-058828 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201113 FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Riker Lauren Bullaro CENTRAL INDEX KEY: 0001545439 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 201322202 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-13 0 0001396814 Pacira BioSciences, Inc. PCRX 0001545439 Riker Lauren Bullaro C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Vice President, Finance Common Stock 2020-11-13 4 M 0 3000 10.81 A 16181 D Common Stock 2020-11-13 4 S 0 3000 63.81 D 13181 D Stock Option (Right to Buy) 10.81 2020-11-13 4 M 0 3000 0.00 D 2022-06-05 Common Stock 3000 17820 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. /s/ Kristen Williams, Attorney-in-Fact 2020-11-17